Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Oct;70(4):775–777. doi: 10.1038/bjc.1994.395

A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.

N M Bleehen 1, A H Calvert 1, S M Lee 1, P Harper 1, S B Kaye 1, I Judson 1, M Brampton 1
PMCID: PMC2033397  PMID: 7917939

Abstract

The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligible for review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for response. The major toxicities were leucopenia and thrombocytopenia. CB10-277 in this schedule therefore does not appear to have major activity in melanoma.

Full text

PDF
775

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baird G. M., Willoughby M. L. Photodegradation of dacarbazine. Lancet. 1978 Sep 23;2(8091):681–681. doi: 10.1016/s0140-6736(78)92794-0. [DOI] [PubMed] [Google Scholar]
  2. Beretta G., Bonadonna G., Bajetta E., Tancini G., De Lena M., Azzarelli A., Veronesi U. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease. Cancer Treat Rep. 1976 Feb;60(2):205–211. [PubMed] [Google Scholar]
  3. Connors T. A., Goddard P. M., Merai K., Ross W. C., Wilman D. E. Tumour inhibitory triazenes: structural requirements for an active metabolite. Biochem Pharmacol. 1976 Feb 1;25(3):241–246. doi: 10.1016/0006-2952(76)90207-0. [DOI] [PubMed] [Google Scholar]
  4. Dorr R. T., Alberts D. S., Einspahr J., Mason-Liddil N., Soble M. Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. Cancer Treat Rep. 1987 Mar;71(3):267–272. [PubMed] [Google Scholar]
  5. Foster B. J., Newell D. R., Carmichael J., Harris A. L., Gumbrell L. A., Jones M., Goodard P. M., Calvert A. H. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer. 1993 Feb;67(2):362–368. doi: 10.1038/bjc.1993.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Foster B. J., Newell D. R., Gumbrell L. A., Jenns K. E., Calvert A. H. Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer. 1993 Feb;67(2):369–373. doi: 10.1038/bjc.1993.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gibson N. W., Hartley J. A., LaFrance R. J., Vaughan K. Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of 1-aryl-3-alkyltriazenes. Cancer Res. 1986 Oct;46(10):4999–5003. [PubMed] [Google Scholar]
  8. Koriech O. M., Shükla V. S. Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light. Clin Radiol. 1981 Jan;32(1):53–55. doi: 10.1016/s0009-9260(81)80251-6. [DOI] [PubMed] [Google Scholar]
  9. Newell D., Gescher A., Harland S., Ross D., Rutty C. N-methyl antitumour agents. A distinct class of anticancer drugs? Cancer Chemother Pharmacol. 1987;19(2):91–102. doi: 10.1007/BF00254559. [DOI] [PubMed] [Google Scholar]
  10. Newlands E. S., Blackledge G. R., Slack J. A., Rustin G. J., Smith D. B., Stuart N. S., Quarterman C. P., Hoffman R., Stevens M. F., Brampton M. H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287–291. doi: 10.1038/bjc.1992.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. SHEALY Y. F., MONTGOMERY J. A., LASTER W. R., Jr Antitumor activity of triazenoimidazoles. Biochem Pharmacol. 1962 Jul;11:674–676. doi: 10.1016/0006-2952(62)90130-2. [DOI] [PubMed] [Google Scholar]
  12. Wilman D. E., Goddard P. M. Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series. J Med Chem. 1980 Sep;23(9):1052–1054. doi: 10.1021/jm00183a017. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES